Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma

被引：131

作者：

Konteatis, Zenon ^{[1
]}

Artin, Erin ^{[1
,7
]}

Nicolay, Brandon ^{[1
]}

Straley, Kimberly ^{[1
,8
]}

Padyana, Anil K. ^{[1
]}

Jin, Lei ^{[1
]}

Chen, Yue ^{[1
]}

Narayaraswamy, Rohini ^{[1
]}

Tong, Shuilong ^{[2
]}

Wang, Feng ^{[3
]}

Zhou, Ding ^{[4
,9
]}

Cui, Dawei ^{[4
,10
]}

Cai, Zhenwei ^{[4
]}

Luo, Zhiyong ^{[5
]}

Fang, Cheng ^{[5
]}

Tang, Huachun ^{[5
]}

Lv, Xiaobing ^{[5
,14
]}

Nagaraja, Raj ^{[1
]}

Yang, Hua ^{[1
]}

Su, Shin-San M. ^{[1
,12
]}

Sui, Zhihua ^{[1
]}

Dang, Lenny ^{[1
]}

Yen, Katharine ^{[1
,13
]}

Popovici-Muller, Janeta ^{[1
,12
]}

Codega, Paolo ^{[6
,11
]}

Campos, Carl ^{[6
]}

Mellinghoff, Ingo K. ^{[6
]}

Biller, Scott A. ^{[1
]}

机构：

[1] Agios Pharmaceut Inc, Cambridge, MA 02139 USA

[2] Viva Biotech, Shanghai 201203, Peoples R China

[3] Wuxi Biortus Biosci Co Ltd, Jiangyin 214437, Peoples R China

[4] PharmaResources, Shanghai 201201, Peoples R China

[5] ChemPartner, Shanghai 201203, Peoples R China

[6] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA

[7] KSQ Therapeut, Cambridge, MA 02139 USA

[8] Vertex Pharmaceut, Boston, MA 02210 USA

[9] Zion Pharma, Shanghai 200000, Peoples R China

[10] Suzhou Zelgen Biopharmaceut, Kunshan 215300, Peoples R China

[11] Sundia, Shanghai 201203, Peoples R China

[12] Decibel Therapeut, Cambridge, MA 02215 USA

[13] Auron Therapeut, Wellesley, MA 02481 USA

[14] Italfarmaco SpA, I-20092 Cinisello Balsamo, Italy

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 02期

关键词：

Isocitrate dehydrogenase; mutant IDH1/mIDH2; AG-881; vorasidenib; 2-hydroxyglutarate; GENOMIC ANALYSIS; MUTATIONS;

D O I：

10.1021/acsmedchemlett.9b00509

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Inhibitors of mutant isocitrate dehydrogenase (mIDH) 1 and 2 cancer-associated enzymes prevent the accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG) and are under clinical investigation for the treatment of several cancers harboring an IDH mutation. Herein, we describe the discovery of vorasidenib (AG-881), a potent, oral, brain-penetrant dual inhibitor of both mIDH1 and mIDH2. X-ray cocrystal structures allowed us to characterize the compound binding site, leading to an understanding of the dual mutant inhibition. Furthermore, vorasidenib penetrates the brain of several preclinical species and inhibits 2-HG production in glioma tissue by >97% in an orthotopic glioma mouse model. Vorasidenib represents a novel dual mIDH1/2 inhibitor and is currently in clinical development for the treatment of low-grade mIDH glioma.

引用

页码：101 / 107

页数：13

共 50 条

[1] Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma
Mellinghoff, Ingo K.
Penas-Prado, Marta
Peters, Katherine B.
Cloughesy, Timothy Francis
Burris, Howard A.
Maher, Elizabeth A.
Janku, Filip
Cote, Gregory Michael
De La Fuente, Macarena Ines
Clarke, Jennifer
Steelman, Lori
Le, Kha
Zhang, Yanwei
Sonderfan, Alison
Hummel, Diana
Schoenfeld, Steven
Yen, Katharine
Pandya, Shuchi Sumant
Wen, Patrick Y.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION
Mellinghoff, Ingo
Penas-Prado, Marta
Peters, Katherine
Cloughesy, Timothy
Burris, Howard
Maher, Elizabeth
Janku, Filip
Cote, Gregory
De La Fuente, Macarena
Clarke, Jennifer
Steelman, Lori
Le, Kha
Xu, Huansheng
Sonderfan, Alison
Hummel, Diana
Schoenfeld, Steven
Yen, Katharine
Pandya, Shuchi
Wen, Patrick
NEURO-ONCOLOGY, 2018, 20 : 18 - 18
[3] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Popovici-Muller, Janeta
Lemieux, Rene M.
Artin, Erin
Saunders, Jeffrey O.
Salituro, Francesco G.
Travins, Jeremy
Cianchetta, Giovanni
Cai, Zhenwei
Zhou, Ding
Cui, Dawei
Chen, Ping
Straley, Kimberly
Tobin, Erica
Wang, Fang
David, Muriel D.
Penard-Lacronique, Virginie
Quivoron, Cyril
Saada, Veronique
De Botton, Stephane
Gross, Stefan
Dang, Lenny
Yang, Hua
Utley, Luke
Chen, Yue
Kim, Hyeryun
Jin, Shengfang
Gu, Zhiwei
Yao, Gui
Luo, Zhiyong
Lv, Xiaobing
Fang, Cheng
Yan, Liping
Olaharski, Andrew
Silverman, Lee
Biller, Scott
Su, Shin-San M.
Yen, Katharine
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305
[4] Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
Ma, Rui
Yun, Cai-Hong
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 503 (04) : 2912 - 2917
[5] Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population.
Mellinghoff, Ingo K.
Peters, Katherine B.
Cloughesy, Timothy Francis
Burris, Howard A., III
Maher, Elizabeth Anne
Janku, Filip
Cote, Gregory Michael
De La Fuente, Macarena Ines
Clarke, Jennifer Leigh
Kha Le
Li Liu
Man Yuen
Arnofsky, Marissa
Hassan, Islam
Steelman, Lori
Pandya, Shuchi Sumant
Wen, Patrick Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS
Mellinghoff, Ingo K.
Touat, Mehdi
Maher, Elizabeth
DeLaFuente, Macarena
Cloughesy, Timothy F.
Holdhoff, Matthias
Cote, Gregory
Burris, Howard
Janku, Filip
Huang, Raymond
Young, Robert
Ellingson, Benjamin
Auer, Julia
Liu, Hua
Hurov, Jonathan
Yen, Katherine
Agresta, Sam
Attar, Eyal
Pandya, Susan
Wen, Patrick Y.
NEURO-ONCOLOGY, 2016, 18 : 12 - 12
[7] Discovery of AG-120: A first-in-class inhibitor of IDH1 mutant enzymes for the treatment of cancers harboring IDH1 mutations
Popovici-Muller, Janeta
Lemieux, Rene
Saunders, Jeffrey
Salituro, Francesco
Yen, Katharine
Straley, Kimberly
Tobin, Erica
Wang, Fang
Gross, Stefan
Artin, Erin
Dang, Lenny
Yang, Hua
Utley, Luke
Chen, Yue
Olaharski, Andrew
Silverman, Lee
Agresta, Sam
Su, Michael
Biller, Scott
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
[8] AG-881, a brain penetrant, potent, pan-mutant IDH (mIDH) inhibitor for use in mIDH solid and hematologic malignancies
Yen, Katharine
Konteatis, Zenon
Sui, Zhihua
Artin, Erin
Dang, Lenny
Straley, Kimberly
Tobin, Erica
Campos, Carl
Yang, Hua
Nagaraja, Raj
Chen, Yue
Kim, Hyeryun
Gliser, Camelia
Nicolay, Brandon
Olaharski, Andrew
Silverman, Lee
Biller, Scott
Su, Shinsan M.
Mellinghoff, Ingo
Popovici-Muller, Janeta
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[9] COMBINED USE OF THE PAN-IDH MUTANT INHIBITOR AG-881 WITH RADIATION THERAPY SHOWS ADDED BENEFIT IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO
Nicolay, Brandon
Narayanaswamy, Rohini
Amatangelo, Michael D.
Aguado, Elia
Nagaraja, Raj
Murtie, Josh
Liu, Guowen
Ishii, Yuko
NEURO-ONCOLOGY, 2017, 19 : 79 - 79
[10] A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS
Mellinghoff, Ingo
Cloughesy, Timothy
Wen, Patrick
Taylor, Jennie
Maher, Elizabeth
Arrillaga-Romany, Isabel
Peters, Katherine
Choi, Changho
Ellingson, Benjamin
Lin, Alexander
Thakur, Sunitha
Nicolay, Brandon
Lu, Min
Le, Kha
Yin, Feng
Tai, Feng
Schoenfeld, Steven
Pandya, Shuchi S.
Hassan, Islam
Steelman, Lori
Clarke, Jennifer
NEURO-ONCOLOGY, 2019, 21 : 28 - 28

← 1 2 3 4 5 →